Welcome to our dedicated page for Nanobiotix S.A. American Depositary Shares news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. American Depositary Shares stock.
Nanobiotix S.A. (Euronext: NANO / ISIN: FR0011341205) is a leading clinical-stage nanomedicine company specializing in the development of groundbreaking approaches for cancer treatment. The company's core technology, NanoXray, augments the effectiveness of radiotherapy, offering a more efficient treatment option for cancer patients. The innovative NanoXray products are designed to be compatible with existing radiotherapy treatments and aim to treat a broad spectrum of solid tumors, such as soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma.
The primary product candidate, NBTXR3, is currently undergoing evaluation for its efficacy in treating soft tissue sarcoma, head and neck cancers, prostate cancer, and liver cancers (both primary and metastases). Additionally, Nanobiotix has partnered with PharmaEngine in Taiwan to conduct trials for head and neck cancer and rectal cancer in the Asia Pacific region.
Nanobiotix has also embarked on a preclinical research program in immuno-oncology, further expanding its portfolio and potential for transformative cancer therapies. NBTXR3 works by magnifying the effects of radiotherapy within tumor cells, thereby enhancing cancer treatment without increasing the dose to surrounding healthy tissues.
Recently, Nanobiotix has been focused on validating the safety and efficacy of RT-activated NBTXR3 by moving to global registration for LA-HNSCC, accounting for the majority of its operational and financial resources. The company plans to provide an updated global development plan for NBTXR3 after further alignment with the Joint Steering Committee (JSC).
In terms of financial performance, Nanobiotix has laid out a cautious strategy, ensuring that it remains well-funded to support ongoing and future operations. Their forward-looking statements highlight the potential risks and uncertainties that could affect their business and financial performance.
For the latest updates, Nanobiotix has scheduled a conference call and webcast on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST. It continues to engage the market, providing transparency to shareholders through various media and regular updates on their progress and milestones.
To keep up with the latest news, visit www.nanobiotix.com.
Nanobiotix (NASDAQ: NBTX) provided a progress update and financial results for 2022, emphasizing advancements in its clinical trials and R&D focus. The ongoing Phase 3 trial, NANORAY-312, is operational in 104 sites across 25 countries, with interim efficacy analysis expected in H2 2024. Financially, the company reported a net loss of €57 million, up from €47 million in 2021, with cash and cash equivalents at €41.4 million as of December 31, 2022. The company anticipates its current cash will suffice until Q3 2023, but cautioned about ongoing risks regarding its going concern status due to substantial operating losses. Key upcoming milestones include final data from Study 102 and pancreatic cancer data from MD Anderson, both expected in H2 2023, while a new Chief Medical Officer is anticipated in Q3 2023.
Nanobiotix (NASDAQ: NBTX) announces it will release its full-year financial results for 2022 on April 24, 2023, after the US market closes. A conference call is scheduled for April 25, 2023, at 2:00 PM CEST/8:00 AM EDT, where CEO Laurent Levy and CFO Bart van Rhijn will discuss year-end results and current business activities. The company is focused on physics-based therapeutic approaches in oncology and has achieved market authorization for its lead product, NBTXR3, in Europe for treating soft tissue sarcoma. Founded in 2003 and headquartered in Paris, Nanobiotix is publicly traded on Euronext and NASDAQ, reflecting its commitment to innovative cancer treatments.
Nanobiotix announced on April 11, 2023, its monthly update regarding the total number of voting rights and shares outstanding. For March 31, 2023, the company reported 34,875,872 shares outstanding and 36,634,849 total voting rights, with 36,612,731 of them exercisable. This disclosure complies with French regulations aimed at ensuring transparency in public companies. Nanobiotix is engaged in pioneering therapeutic approaches for treating solid tumors, notably through its lead product, NBTXR3, targeting head and neck cancers. Further information about the company and its innovations can be found on their official website.
Nanobiotix (NASDAQ: NBTX), a clinical biotechnology company focused on cancer treatment, has announced a postponement of its full-year 2022 financial results originally set for March 28, 2023, and its conference call on March 29, 2023. The decision is made to provide additional time for year-end closing procedures. The company will issue a future press release to update stakeholders on the new schedule. Nanobiotix is recognized for its innovative physics-based therapeutic approaches and has developed NBTXR3, which has received market approval in Europe for treating soft tissue sarcoma.
FAQ
What is the current stock price of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is the market cap of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is Nanobiotix S.A. known for?
What is NanoXray technology?
What types of cancer does NBTXR3 target?
Who is Nanobiotix partnered with in the Asia Pacific region?
What recent projects are Nanobiotix involved in?
When is the next conference call and webcast scheduled?
How does NBTXR3 enhance radiotherapy?
What is the significance of Nanobiotix’s preclinical research program?
Where can I find more information about Nanobiotix?
